Last reviewed · How we verify
PF-04217329
At a glance
| Generic name | PF-04217329 |
|---|---|
| Sponsor | Pfizer |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Phase 2 Study Of The 24-Hour Intraocular Pressure Lowering And Systemic Exposure Of PF-04217329 (PHASE2)
- Safety and Efficacy of PF-04217329 in Patients With Glaucoma or Elevated Eye Pressure. (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PF-04217329 CI brief — competitive landscape report
- PF-04217329 updates RSS · CI watch RSS
- Pfizer portfolio CI